Detalles de la búsqueda
1.
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
BMC Infect Dis
; 18(1): 186, 2018 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669531
2.
Linkages between observed, modeled Saharan dust loading and meningitis in Senegal during 2012 and 2013.
Int J Biometeorol
; 60(4): 557-75, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26296434
3.
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
J Infect Dis
; 212(4): 531-41, 2015 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25722291
4.
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
J Infect Dis
; 211(5): 801-10, 2015 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25293368
5.
Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
J Infect Dis
; 210(11): 1800-10, 2014 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24973461
6.
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
BMC Infect Dis
; 14: 142, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24628789
7.
Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults.
J Formos Med Assoc
; 111(6): 333-9, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22748624
8.
Immunogenicity profile of a 3.75-µg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.
J Infect Dis
; 203(8): 1054-62, 2011 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21450995
9.
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
J Clin Immunol
; 31(3): 443-54, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21174144
10.
Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
J Formos Med Assoc
; 110(12): 780-6, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22248833
11.
Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
J Med Assoc Thai
; 94(8): 916-26, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21863672
12.
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.
Hum Vaccin Immunother
; 17(11): 4132-4143, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34190658
13.
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
Pediatr Infect Dis J
; 40(9): e333-e339, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34285165
14.
A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
BMC Infect Dis
; 10: 338, 2010 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-21108818
15.
Characterization of Bacteria on Aerosols From Dust Events in Dakar, Senegal, West Africa.
Geohealth
; 4(6): e2019GH000216, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490303
16.
Observed and Modeled Seasonal Air Quality and Respiratory Health in Senegal During 2015 and 2016.
Geohealth
; 3(12): 423-442, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32159028
17.
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
Lancet
; 370(9587): 580-9, 2007 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-17707753
18.
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
Vaccine
; 35(46): 6321-6328, 2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28987445
19.
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Vaccine
; 35(35 Pt B): 4621-4628, 2017 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28720281
20.
Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
Pediatr Infect Dis J
; 35(2): e35-47, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26551446